INTRODUCTION: Whereas in the adult population 5-Aminolevulinic acid (5-ALA) fluorescence guidance has been widely accepted for improving the extent of tumor resection, the application in children remains an off-label use. Even though most pediatric study protocols require a complete resection for improving outcome parameters, only few pediatric patients have been operated with fluorescence guidance, and it remains questionable, whether and which pediatric tumors show useful fluorescence. We present casuistic reports of application of 5-ALA in children collected from three different neurosurgical departments. PATIENTS AND METHODS: In children with suspected malignant intracerebral tumor or recurrence, individual informed consent was obtained in each case from the parents. 5-ALA was administered according to the adult protocol, with 20 mg/kg, 2 h before induction of anesthesia. We retrospectively analyzed 18 patients (13 male, 5 female; age 3-18 years), using the intraoperative neurosurgical protocol, the postoperative MRI results, and the follow-up clinical examinations. RESULTS: The use of 5-ALA fluorescence guidance proved to be safe in our group of pediatric patients. Fluorescence guidance was most useful for recurrent glioblastoma resection. Medulloblastoma tissue displayed fluorescence only inconsistently, and most pilocytic astrocytoma remained without staining. Ganglioglioma showed partial staining in the central tumor areas, without allowing the use for circumferent resection. CONCLUSION: The off-label use of 5-ALA fluorescence guidance in pediatric patients appears to be most useful in recurrent high-grade gliomas. Fluorescence accumulation in other pediatric brain tumor entities is not predictable and should be evaluated in future clinical studies before being integrated into the current treatment protocols.
INTRODUCTION: Whereas in the adult population 5-Aminolevulinic acid (5-ALA) fluorescence guidance has been widely accepted for improving the extent of tumor resection, the application in children remains an off-label use. Even though most pediatric study protocols require a complete resection for improving outcome parameters, only few pediatric patients have been operated with fluorescence guidance, and it remains questionable, whether and which pediatric tumors show useful fluorescence. We present casuistic reports of application of 5-ALA in children collected from three different neurosurgical departments. PATIENTS AND METHODS: In children with suspected malignant intracerebral tumor or recurrence, individual informed consent was obtained in each case from the parents. 5-ALA was administered according to the adult protocol, with 20 mg/kg, 2 h before induction of anesthesia. We retrospectively analyzed 18 patients (13 male, 5 female; age 3-18 years), using the intraoperative neurosurgical protocol, the postoperative MRI results, and the follow-up clinical examinations. RESULTS: The use of 5-ALA fluorescence guidance proved to be safe in our group of pediatric patients. Fluorescence guidance was most useful for recurrent glioblastoma resection. Medulloblastoma tissue displayed fluorescence only inconsistently, and most pilocytic astrocytoma remained without staining. Ganglioglioma showed partial staining in the central tumor areas, without allowing the use for circumferent resection. CONCLUSION: The off-label use of 5-ALA fluorescence guidance in pediatric patients appears to be most useful in recurrent high-grade gliomas. Fluorescence accumulation in other pediatric brain tumor entities is not predictable and should be evaluated in future clinical studies before being integrated into the current treatment protocols.
Authors: S Eicker; S Sarikaya-Seiwert; A Borkhardt; K Gierga; B Turowski; H-J Heiroth; H-J Steiger; W Stummer Journal: Cent Eur Neurosurg Date: 2010-10-07
Authors: David W Roberts; Pablo A Valdés; Brent T Harris; Alexander Hartov; Xiaoyao Fan; Songbai Ji; Frederic Leblond; Tor D Tosteson; Brian C Wilson; Keith D Paulsen Journal: Neurosurg Clin N Am Date: 2012-07 Impact factor: 2.509
Authors: Stefan Rieken; Angela Mohr; Daniel Habermehl; Thomas Welzel; Katja Lindel; Olaf Witt; Andreas E Kulozik; Wolfgang Wick; Jürgen Debus; Stephanie E Combs Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-23 Impact factor: 7.038
Authors: E Susan Amirian; Terri S Armstrong; Kenneth D Aldape; Mark R Gilbert; Michael E Scheurer Journal: Neuroepidemiology Date: 2012-07-28 Impact factor: 3.282
Authors: Marcel A Kamp; Antonio Santacroce; Samis Zella; Dorothea C Reichelt; Jörg Felsberg; Hans-Jakob Steiger; Jan Frederick Cornelius; Michael Sabel Journal: Acta Neurochir (Wien) Date: 2012-05-11 Impact factor: 2.216
Authors: Bassel Zebian; Francesco Vergani; José Pedro Lavrador; Soumya Mukherjee; William John Kitchen; Vita Stagno; Christos Chamilos; Benedetta Pettorini; Conor Mallucci Journal: CNS Oncol Date: 2016-12-21
Authors: Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius Journal: Neurosurg Rev Date: 2016-05-25 Impact factor: 3.042
Authors: Derek Yecies; Orly Liba; Elliott D SoRelle; Rebecca Dutta; Edwin Yuan; Hannes Vogel; Gerald A Grant; Adam de la Zerda Journal: Sci Rep Date: 2019-07-17 Impact factor: 4.379
Authors: Alexander J Schupper; Manasa Rao; Nicki Mohammadi; Rebecca Baron; John Y K Lee; Francesco Acerbi; Constantinos G Hadjipanayis Journal: Front Neurol Date: 2021-06-16 Impact factor: 4.003
Authors: Walter Stummer; Floriano Rodrigues; Philippe Schucht; Matthias Preuss; Dorothee Wiewrodt; Ulf Nestler; Marco Stein; José Manuel Cabezudo Artero; Nunzio Platania; Jane Skjøth-Rasmussen; Alessandro Della Puppa; John Caird; Søren Cortnum; Sam Eljamel; Christian Ewald; Laura González-García; Andrew J Martin; Ante Melada; Aurelia Peraud; Angela Brentrup; Thomas Santarius; Hans Herbert Steiner Journal: Acta Neurochir (Wien) Date: 2014-09-24 Impact factor: 2.216
Authors: Julius Höhne; Francesco Acerbi; Jacopo Falco; Mehmet Osman Akçakaya; Nils Ole Schmidt; Talat Kiris; Camilla de Laurentis; Paolo Ferroli; Morgan Broggi; Karl-Michael Schebesch Journal: J Clin Med Date: 2020-07-28 Impact factor: 4.241